Famotidine and Lockdowns - COVID Solutions?

The world of COVID-19 is always changing. Join Geoff Wall for a rapid fire of updates regarding famotidine, lockdowns, and ivermectin as evaluated for efficacy in COVID-19. The GameChangers The use of high-dose famotidine in the treatment of COVID-19 has demonstrated moderate safety, but questionable efficacy. Additionally, a recent meta-analysis examining the efficacy of lockdown on the spread of COVID-19 had several limitations that should be taken into consideration. Show Segments 00:00 – Introductions 01:56 – Famotidine in the Treatment of COVID-19 10:52 – Effects of Lockdown on COVID-19 Mortality 18:26 – Ivermectin Treatment of COVID-19 in High-Risk Patients 23:45 – Closing Remarks Host Geoff Wall, PharmD., BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health Redeem your CPE or CME credit here! Pharmacist members CME Need a membership? Join for CPE Credit Join for CME Credit References and resources: References and resources: 1. Oral Famotidine Versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blind, Data-Intense, Phase 2 Clinical Trial 2. A Literature Review and Meta-Analysis of the Effects of Lockdowns on COVID-19 Mortality. Pre-Publication. 3. Efficacy of Ivermectin Treatment on Disease Progression Among Adults with Mild to Moderate COVID-19 and Comorbidities Continuing Education Information: Learning Objectives: 1. Describe the latest information on masks and other non-pharmacologic interventions to halt the spread of COVID-19 2. Discuss the recent randomized controlled trial evaluating famotidine use in early COVID-19 positive patients Dr. Wall is a member of the Janssen Speaker's Bureau. 0.05 CEU | 0.5 Hrs ACPE UAN: 0107-0000-22-142-H01-P Initial release date: 03/28/22 Expiration date: 03/28/2023 Follow CEimpact on Social Media: LinkedIn Instagram